# Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs

> **NIH CA U01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2026 · $766,920

## Abstract

PROJECT SUMMARY / ABSTRACT
To diagnose pancreatic ductal adenocarcinoma (PDAC) in its precursor or early stages, novel screening tools
must apply liquid biomarkers with localization using novel imaging strategies in high-risk populations. The OHSU
PCDC Research Unit proposes three aims highlighting its multidisciplinary strengths in cancer biology, imaging,
and implementation science. The overarching theme of the proposed research focuses on sensitivity, feasibility,
and patient acceptability. Our sensitive blood-based screening test can be applied with minimal quantities of
blood and is easily modifiable based on further discoveries. If positive, this would prompt application of a feasible,
non-contrast, and robust magnetic resonance imaging (MRI) protocol that augments MRI and magnetic
resonance chlangiopancreatography (MRCP) of the pancreas with quantitatively rigorous MR Fingerprinting
(MRF). MRF can simultaneously quantify parameters that are associated with fibrosis and inflammation (T1, T2,
and T1p). We hypothesize that these parameters are upregulated in high-grade dysplasia (e.g., high-risk
intraductal papillary mucinous neoplasms (IPMNs) and grade 2-3 pancreatic intraepithelial neoplasia (PanIN))
and early-stage pancreatic ductal adenocarcinoma (PDAC). Further, quantitative MRI will reduce the high
interobserver variability of MR interpretation and requirement for time consuming and technically complex MR
protocols that can be challenging to implement outside of pancreas referral centers. If successful, MRF may
obviate the need for Gadolinium based contrast agents in screening populations undergoing frequent MRI and
MRCP. Finally, we will increase enrollment of high-risk individuals into PCDC Signature Cohorts, through
leveraging an existing large, statewide cohort, Healthy Oregon Project. Further, we will work collaboratively with
our Community Outreach, Research & Engagement team to understand and address barriers to engagement in
PDAC surveillance among

## Key facts

- **NIH application ID:** 11318983
- **Project number:** 5U01CA278923-04
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Gregory A Cote; Alexander Savio Ramos Guimaraes; ROSALIE C SEARS; Brett c Sheppard
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $766,920
- **Award type:** 5
- **Project period:** 2023-05-15T00:00:00 → 2028-04-30T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11318983

## Citation

> US National Institutes of Health, RePORTER application 11318983, Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs (5U01CA278923-04). Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/grant/nih/11318983. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*